|
25 May 2018 |
Splash Pharmaceuticals Announces Dose Escalation in Phase I Clinical Trial in Platinum-resistant Ovarian Cancer Patients
|
|
25 May 2018 |
BioMarin Receives Standard Approval for Palynziq™ (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease
|
|
25 May 2018 |
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
|
|
23 May 2018 |
FDA Accepts Supplemental Biologics License Application (BLA) and Grants Priority Review for Prophylactic and Pediatric Use for Bio Products Laboratory's Coagadex® (Coagulation Factor X, Human) for Treatment of Hereditary Factor X Deficiency
|
|
23 May 2018 |
Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients
|
|
22 May 2018 |
Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute
|
|
22 May 2018 |
Bioverativ Presents Preliminary Phase 1/2a Data on BIVV001, the First Factor VIII Therapy to Break Through the VWF Half-Life Ceiling in Hemophilia A
|
|
17 May 2018 |
Obsidian Presents Preclinical Data at ASGCT Showing Advancement of Its Regulated IL12 and IL15 Programs to Enable Safer and More Effective CAR-T Therapies
|
|
17 May 2018 |
Evolus Announces Progress with DWP-450 Regulatory Submissions
|
|
15 May 2018 |
Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018
|
|
15 May 2018 |
FDA approves first epoetin alfa biosimilar for the treatment of anemia
|
|
09 May 2018 |
Bonti Announces Start of LANTERN-2 Phase 2 Clinical Trial Evaluating EB-001T in Treating Focal Muscle Pain
|
|
09 May 2018 |
Palatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts
|
|
09 May 2018 |
Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients
|
|
08 May 2018 |
Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
|
|
08 May 2018 |
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP
|
|
05 May 2018 |
U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors
|
|
03 May 2018 |
Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
|
|
02 May 2018 |
Bioniz Therapeutics Announces Positive Phase 1b Clinical Study Results for Investigational Agent BNZ-1
|
|
30 Apr 2018 |
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
|
|
30 Apr 2018 |
Medtronic Announces FDA Approval of Infuse(TM) Bone Graft in New Spine Surgery Indications Using PEEK Interbody Implants
|
|
25 Apr 2018 |
Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer's Disease
|
|
24 Apr 2018 |
New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors
|
|
19 Apr 2018 |
Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo
|
|
19 Apr 2018 |
AzurRx BioPharma Announces Positive Preclinical Data with AZX1103
|
